CoChat
Sign Up
Cited by 224Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCerebrospinal fluid and hydrocephalus

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease

Zetterberg, Henrik, Andreasson, Ulf, Hansson, Oskar, Wu, Guoxin, Sankaranarayanan, Sethu, Andersson, Malin E., Buchhave, Peder, Londos, Elisabet, Umek, Robert M., Minthon, Lennart, Simon, Adam J., Blennow, Kaj·2008·Archives of Neurology
DOI 10.1001/archneur.65.8.1102
Open this paper in CoChat — free account

Abstract

BACKGROUND: We used a sensitive and specific beta-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) assay to determine the relationship between BACE1 activity in cerebrospinal fluid (CSF) and markers of APP metabolism and axonal degeneration in early and late stages of Alzheimer disease (AD). OBJECTIVE: To assess CSF BACE1 activity in AD. DESIGN: Case-control and longitudinal follow-up study. SETTING: Specialized memory clinic. Patients Eighty-seven subjects with AD, 33 cognitively normal control subjects, and 113 subjects with mild cognitive impairment (MCI), who were followed up for 3 to 6 years. MAIN OUTCOME MEASURES: Cerebrospinal fluid BACE1 activity in relation to diagnosis and CSF levels of secreted APP and amyloid beta protein (Abeta) isoforms and the axonal degeneration marker total tau. RESULTS: Subjects with AD had higher CSF BACE1 activity (median, 30 pM [range, 11-96 pM]) than controls (median, 23 pM [range, 8-43 pM]) (P =.02). Subjects with MCI who progressed to AD during the follow-up period had higher baseline BACE1 activity (median, 35 pM [range, 18-71 pM]) than subjects with MCI who remained stable (median, 29 pM [range, 14-83 pM]) (P < .001) and subjects with MCI who developed other forms of dementia (median, 20 pM [range, 10-56 pM]) (P <.001). BACE1 activity correlated positively with CSF levels of secreted APP isoforms and Abeta(40) in the AD and control groups and in all MCI subgroups (P < .05) except the MCI subgroup that developed AD. Strong positive correlations were found between CSF BACE1 activity and total tau levels in all MCI subgroups (r >or= 0.57, P

Overview

Integrity signals

Registry

Crossref · 10.1001/archneur.65.8.1102

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 23 references

Cited by

Sorted by citations

Items 201–223 of 223

Related

See all

Metadata

Authors
Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., Buchhave, P., Londos, E., Umek, R. M., Minthon, L., Simon, A. J., & Blennow, K.
Affiliations
University of Gothenburg (SE)
ORCID
Venue
Archives of Neurology
Publisher
American Medical Association (AMA)
Published
2008-08-01
Volume
65
Issue
8
Pages
1102-7
ISSN
0003-9942 (ISSN-L)
DOI
10.1001/archneur.65.8.1102
OpenAlex
W2117635180
Cited by
224
References
23
Citations by year
2025: 4 · 2024: 8 · 2023: 6 · 2022: 12 · 2021: 11 · 2020: 9 · 2019: 11 · 2018: 18 · 2017: 7 · 2016: 10 · 2015: 20 · 2014: 15 · 2013: 26 · 2012: 21
FWCI
10.16
Type
journal article
Language
en
Open access
closed
Locations
  • Archives of Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
cerebrospinal fluid, Alzheimer's disease, mild cognitive impairment, amyloid precursor protein, amyloid-beta, total tau, axonal degeneration, APP metabolism, biomarkers, disease progression
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Axons, Enzyme Activation, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Nerve Degeneration, Biomarkers, Case-Control Studies, Aspartic Acid Endopeptidases, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review